Evidence map›Paper›PMID 32289256›Full record

ReviewTranslational research : the journal of laboratory and clinical medicine2020

Sex related differences in the pathogenesis of organ fibrosis.

Alejandra Garate-Carrillo, Julisa Gonzalez, Guillermo Ceballos, Israel Ramirez-Sanchez, Francisco Villarreal

Open access · greenAbstract readReview
In one paragraph

Review in Translational research : the journal of laboratory and clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 70 citations in OpenAlex.

  1. Article
  2. Acute and Chronic Myocarditis in Men and Women.Current heart failure reports · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Alejandra Garate-CarrilloDepartment of Medicine, School of Medicine, University of California, San Diego, California; Seccion de Estudios de Posgrado e Investigacion, Escuela Superior de Medicina, Instituto Politecnico Nacional, Mexico city, Mexico.
Julisa GonzalezDepartment of Medicine, School of Medicine, University of California, San Diego, California.
Guillermo CeballosSeccion de Estudios de Posgrado e Investigacion, Escuela Superior de Medicina, Instituto Politecnico Nacional, Mexico city, Mexico.
Israel Ramirez-SanchezDepartment of Medicine, School of Medicine, University of California, San Diego, California; Seccion de Estudios de Posgrado e Investigacion, Escuela Superior de Medicina, Instituto Politecnico Nacional, Mexico city, Mexico.
Francisco VillarrealDepartment of Medicine, School of Medicine, University of California, San Diego, California; VA San Diego Health Care, San Diego, California. Electronic address: fvillarr@ucsd.edu.
University of California, San Diego · USInstituto Politécnico Nacional · MX

Funding

Epicatechin and derivatives to preserve muscle structure function in diabetesR01DK098717 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HENRY, ROBERT ROY, VILLARREAL, FRANCISCO J · 2014 to 2017
$1.4M
Epicatechin treatment for sarcopeniaR21AG047326 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI VILLARREAL, FRANCISCO J · 2015 to 2015
$233k
Excess O-GlcNAc modification of proteins and myocardial fibrosisI01BX003230 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI VILLARREAL, FRANCISCO J · 2018 to 2021
–
BLRD VA I01 BX003230NIA NIH HHS R21 AG047326NIDDK NIH HHS R01 DK098717
6 · The paper itself

Abstract

The development of organ fibrosis has garnered rising attention as multiple diseases of increasing and/or high prevalence appear to progress to the chronic stage. Such is the case for heart, kidney, liver, and lung where diseases such as diabetes, idiopathic/autoimmune disorders, and nonalcoholic liver disease appear to notably drive the development of fibrosis. Noteworthy is that the severity of these pathologies is characteristically compounded by aging. For these reasons, research groups and drug companies have identified fibrosis as a therapeutic target for which currently, there are essentially no effective options. Although a limited body of published studies are available, most literature indicates that in multiple organs, premenopausal women are protected from developing severe forms of fibrosis suggesting an important role for sex hormones in mitigating this process. Investigators have implemented relevant animal models of organ disease linked to fibrosis supporting in general, these observations. In vitro studies and transgenic animals models have also been used in an attempt to understand the role that sex hormones and related receptors play in the development of fibrosis. However, in the setting of chronic disease in some organs such as the heart older (postmenopausal) women within a few years can quickly approach men in disease severity and develop significant degrees of fibrosis. This review summarizes the current body of relevant literature and highlights the imperative need for a major focus to be placed on understanding the manner in which sex and the presence or absence of related hormones modulates cell phenotypes so as to allow for fibrosis to develop.

Indexed as

Organ SpecificitySex CharacteristicsAnimalsDisease Models, AnimalFemaleFibrosisHumansMale

Identifiers

PMID32289256
PMCPMC7721117
OpenAlexW3012438373

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.